NCT00093080View on ClinicalTrials.gov

Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)

PHASE2CompletedINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
LeiomyosarcomaLiposarcomaOsteosarcomaSarcoma, Soft TissueMetastases
Interventions
DRUG

ridaforolimus

12.5 mg of ridaforolimus is given intravenously over 30 minutes once daily for 5 days, every 2 weeks

Sponsors

Collaborators (1)

Ariad Pharmaceuticals
All Listed Sponsors
collaborator

Ariad Pharmaceuticals

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00093080 - Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) | Biotech Hunter | Biotech Hunter